Castelvecchio Pascoli (Lucca, Italy), 31 January 2021– Kedrion Biopharma CEO Val Romberg has completed his assignment at the Italian-based international pharmaceuticals company. Mr.Romberg took on the role in 2020 and led the group through a process of transformation that contributed to the success of the recent agreement between Kedrion shareholders and Permira, the UK-based private equity fund.
“I thoroughly enjoyed my time at Kedrion and wish the Marcucci family and Permira the very best as they embark upon new international growth,” said Mr. Romberg.
Paolo Marcucci, the Kedrion chairman, thanked Mr. Romberg for his service and said: “On behalf of the Marcucci family and the Board of Directors of Kedrion we wish Val a future of further professional and personal satisfaction.”
The Board of Kedrion has meanwhile asked Mr. Marcucci to assume the role of Executive Chairman following Mr. Romberg’s departure, with full strategic and management responsibility for the group.